Improved Leverage (debt-to-equity)A lower debt-to-equity ratio materially reduces financial risk and interest burden, improving flexibility to fund R&D and commercial expansion. Over 2–6 months, sustained low leverage supports resilience through surgical sales cycles and reduces refinancing vulnerability.

Revenue Growth RecoveryPositive revenue growth indicates improving product demand and market traction in orthopedics. If sustained, this trend supports scale benefits, better margin absorption of fixed costs, and strengthens the platform for distributor/clinic partnerships over the medium term.

Strong Free Cash Flow Growth RateA large percentage increase in FCF signals operational improvement and progress toward cash generation. Even off a low base, continued FCF growth can enable self-funded investments in product development and post-sales service capabilities, improving long-term sustainability.

Bears Say

Persistent Negative ProfitabilityNegative operating and reported profits show the company is not yet converting sales into sustainable earnings. Persisting margin deficits constrain reinvestment, make break-even distant, and can force pricing or cost trade-offs that weaken competitive positioning over months.

Negative Operating And Free Cash FlowsOngoing negative cash generation creates reliance on external funding or equity dilution to finance operations and growth. Over a multi-month horizon this limits flexibility for marketing, new product launches, and inventory support in a device business with surgical timing spikes.

Negative Return On EquityA negative ROE signals capital is not generating shareholder value and indicates weak operational efficiency. This undermines investor confidence, may raise cost of capital, and restricts the firm's ability to attract funding for product development and distribution expansion long term.

AAQ1 FAQ

What was aap Implantate AG’s price range in the past 12 months?

aap Implantate AG lowest stock price was €1.08 and its highest was €2.00 in the past 12 months.

What is aap Implantate AG’s market cap?

aap Implantate AG’s market cap is €21.19M.

When is aap Implantate AG’s upcoming earnings report date?

aap Implantate AG’s upcoming earnings report date is Jul 07, 2026 which is in 132 days.

How were aap Implantate AG’s earnings last quarter?

Currently, no data Available

Is aap Implantate AG overvalued?

According to Wall Street analysts aap Implantate AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does aap Implantate AG pay dividends?

aap Implantate AG does not currently pay dividends.

What is aap Implantate AG’s EPS estimate?

aap Implantate AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does aap Implantate AG have?

aap Implantate AG has 14,716,976 shares outstanding.

What happened to aap Implantate AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of aap Implantate AG?

Currently, no hedge funds are holding shares in DE:AAQ1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

aap Implantate Stock Smart Score

Neutral

Insider Transactions

Bought Shares

Worth €306.9K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

-34.28%

Trailing 12-Months

Asset Growth

-27.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

aap Implantate AG

aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.